|
1
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian Cancer Statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schiller W: Mesonephroma ovarii. Am J
Cancer. 35:1–21. 1939.
|
|
3
|
Serov SF, Scully RE and Sobin LH:
Histologic Typing of Ovarian Tumors. International histologic
classification of tumors. 9. World Health Organization; Geneva:
1973
|
|
4
|
Kennedy AW, Biscotti CV, Hart WR and
Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol.
32:342–349. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takano M, Kikuchi Y, Yaegashi N, Kuzuya K,
Ueki M, Tusda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, et al:
Clear cell carcinoma of the ovary: A retrospective multicentre
experience of 254 patients with complete surgical staging. Br J
Cancer. 94:1369–1374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistic, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kikuchi Y, Hirata J, Ishii K, Kita and
Nagata I: Complexity of cisdiamminedichloroplatinum (II) resistance
mechanisms in human ovarian cancer cells. The Mechanism of
Cisplatin Resistance and its Circumvention. Nova Science Pub Inc.;
New York, NY: pp. 157–174. 1998
|
|
8
|
Tan DS and Kaye S: Ovarian clear cell
adenocarcinoma: A continuing enigma. J Clin Pathol. 60:355–360.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jenison EL, Montag AG, Griffiths CT, Welch
WR, Lavin PT, Greer J and Knapp RC: Clear cell adenocarcinoma of
the ovary: A clinical analysis and comparison with serous
carcinoma. Gynecol Oncol. 32:65–71. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kennedy AW, Markman M, Biscotti CV, Emery
JD and Rybicki LA: Survival probability in ovarian clear cell
adenocarcinoma. Gynecol Oncol. 74:108–114. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoonessi M, Weldon D, Satchidand SK and
Crickard K: Clear cell ovarian adenocarcinoma. J Surg Oncol.
27:289–297. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sugiyama T, Kamura T, Kigawa J, Terakawa
N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical
characteristics of clear cell carcinoma of the ovary: A distinct
histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan JK, Teoh D, Hu JM, Shin JY, Osann K
and Kapp DS: Do clear cell ovarian carcinoma have poorer prognosis
compared to other epithelial cell type? A study of 1411 clear cell
ovarian cancers. Gynecol Oncol. 109:370–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rauh-Hain AJ, Winograd D, Growdon WB,
Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS and
Del Carmen MG: Prognostic determinants in patients with uterine and
ovarian clear cell carcinoma. Gynecol Oncol. 125:376–380. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Itamochi H, Kigawa J, Sugiyama T, Kikuchi
Y, Suzuki M and Terakawa N: Low proliferation activity may be
associated with chemoresistance in clear cell carcinoma of the
ovary. Obstet Gynecol. 100:281–7. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alexandre J, Ray-Coquard I, Selle F,
Floquet A, Cottu P, Weber B, Falandry C, Lebrun D and
Pujade-Lauraine E: GINECO: Mucinous advanced epithelial ovarian
carcinoma: clinical presentation and sensitivity to
platinumpaclitaxel-based chemotherapy, the GINECO experience. Ann
Oncol. 21:2377–2381. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakayama K, Takebayashi Y, Nakayama S,
Hata K, Fujiwaki R, Fukumoto M and Miyazaki K: Prognostic value of
overexpression of p53 in human ovarian carcinoma patients receiving
cisplatin. Cancer Lett. 192:227–235. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimada M, Kigawa J, Ohishi Y, Yasuda M,
Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T and Kaku T:
Clinicopathological characteristics of mucinous adenocarcinoma of
the ovary. Gynecol Oncol. 113:331–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Omura GA, Brady MF, Homsley HD, Yordan E,
Major FJ, Buchsbaum HJ and Park RC: Long-term follow-Up and
prognostic factor analysis in advanced ovarian carcinoma: The
Gynecologic Oncology Group experience. J Clin Oncol. 9:1138–1150.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Makar AP, Baekelandt M, Troppe CG and
Kristensen GB: The prognostic significance of residual disease,
FIGO substage, tumor histology, and grade in patients with FIGO
stage III ovarian cancer. Gynecol Oncol. 56:175–180. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cannistra SA: Cancer of the ovary. N Eng J
Med. 351:2519–2529. 2004. View Article : Google Scholar
|
|
22
|
Trimbos JB, Vergote I, Bolis G, Vermorken
JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone
G, et al: Impact of adjuvant chemotherapy and surgical staging in
early-stage ovarian carcinoma: European organization for research
and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm
trial. J Natl Cancer Inst. 95:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oseledchyk A, Leitao MM Jr, Konner J,
O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, Long Roche K,
Aghajanian CA, Grisham RN, et al: Adjuvant chemotherapy in patients
with stage I endometrioid or clear cell ovarian cancer in the
platinum era: A surveillance, epidemiology, and end results cohort
study, 2000–2013. Ann Oncol. 28:2985–2993. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rubin SC, Wong GY, Curtin JP, Barakat RR,
Hakes TB and Hoskins WJ: Platinum-based chemotherapy of high-risk
stage I epithelial ovarian cancer following comprehensive surgical
staging. Obstet Gynecol. 82:143–147. 1993.PubMed/NCBI
|
|
25
|
Dembo AJ, Bush RS, Beale FA, Bean HA,
Pringle JF, Sturgeon J and Reid JG: Ovarian carcinoma: Improved
survival following abdominopelvic irradiation in patients with a
completed pelvic operation. Am J Obstet Gynecol. 134:793–800. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sorbe B; Swedish-Norgewian Ovarian Cancer
Study Group, : Consolidation treatment of advanced (FIGO stage III)
ovarian carcinoma in complete surgical remission after induction
chemotherapy: A randomized, controlled, clinical trial comparing
whole abdominal radiotherapy, chemotherapy, and no further
treatment. Int J Gynecol Cancer. 13:278–286. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Patel SC, Frandsen J, Bhatia S and Gaffney
D: Impact on survival with adjuvant radiotherapy for clear cell,
mucinous, and endometrioid ovarian cancer: The SEER experience from
2004 to 2011. J Gynecol Oncol. 27:e452016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parker D, Bradley C, Bogle SM, Lay J,
Masood M, Hancock AK, Naylor B and Price JJ: Serum albumin and
CA125 are powerful predictors of survival in epithelial ovarian
cancer. Br J Obstet Gynecol. 101:888–893. 1994. View Article : Google Scholar
|
|
29
|
Fisken J, Leonard RC, Stewart M, Beattie
GJ, Sturgeon C, Aspinall L and Roulston JE: The prognostic value of
early CA125 serum assay in epithelial ovarian carcinoma. Br J
Cancer. 68:140–145. 1993. View Article : Google Scholar : PubMed/NCBI
|
